Abstract:OBJECTIVE— Acute activation of G protein–coupled receptor 40 (GPR40) by free fatty acids (FFAs) or synthetic GPR40 agonists enhances insulin secretion. However, it is still a matter of debate whether activation of GPR40 would be beneficial for the treatment of type 2 diabetes, since chronic exposure to FFAs impairs islet function. We sought to evaluate the specific role of GPR40 in islets and its potential as a therapeutic target using compounds that specifically activate GPR40. RESEARCH DESIGN AND METHODS— We developed a series of GPR40-selective small-molecule agonists and studied their acute and chronic effects on glucose-dependent insulin secretion (GDIS) in isolated islets, as well as effects on blood glucose levels during intraperitoneal glucose tolerance tests in wild-type and GPR40 knockout mice (GPR40−/−). RESULTS— Small-molecule GPR40 agonists significantly enhanced GDIS in isolated islets and improved glucose tolerance in wild-type mice but not in GPR40−/− mice. While a 72-h exposure to FFAs in tissue culture significantly impaired GDIS in islets from both wild-type and GPR40−/− mice, similar exposure to the GPR40 agonist did not impair GDIS in islets from wild-type mice. Furthermore, the GPR40 agonist enhanced insulin secretion in perfused pancreata from neonatal streptozotocin-induced diabetic rats and improved glucose levels in mice with high-fat diet–induced obesity acutely and chronically. CONCLUSIONS— GPR40 does not mediate the chronic toxic effects of FFAs on islet function. Pharmacological activation of GPR40 may potentiate GDIS in humans and be beneficial for overall glucose control in patients with type 2 diabetes.

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: the Biological Characteristics and the Chemical Space

Advances in Small-Molecule GPR40 Agonists for Treatment of Type 2 Diabetes Mellitus

Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.

Optimization of GPR40 Agonists for Type 2 Diabetes.

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

GPR40-a potential target for diebete mellitus

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models

Discovery of Orally Effective and Safe GPR40 Agonists by Incorporating a Chiral, Rigid and Polar Sulfoxide into Β-Position to the Carboxylic Acid.

De novo Design of G Protein-Coupled Receptor 40 Peptide Agonists for Type 2 Diabetes Mellitus Based on Artificial Intelligence and Site-Directed Mutagenesis

Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.

Discovery of Pyrrolidine-Containing Gpr40 Agonists: Stereochemistry Effects A Change in Binding Mode

Amg 837: A Novel Gpr40/Ffa1 Agonist That Enhances Insulin Secretion And Lowers Glucose Levels In Rodents

Physiology and therapeutics of the free fatty acid receptor GPR40.

Discovery of Novel Potent GPR40 Agonists Containing Imidazo[1,2-A]pyridine Core As Antidiabetic Agents.

Novel DPP-4 Inhibitors Against Diabetes

Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into 8-position to the carboxylic acid

GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates